IFNB1 and myeloid sarcoma: Beta interferons (IFNβ) were the first disease-modifying therapies to be approved in 1993, offering clinicians a valuable tool to reduce the number of relapses and to postpone the onset of disability in relapsing–remitting MS patients [81].